Skip to main content

Table 1 Patient demographics

From: Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study

Parameter Group 1 (1 × 6 mL) Group 2 (1 × 4 mL) Group 3 (2 × 4 mL) Group 4 (3 × 4 mL) Group 5 (3 × 2 mL) Overall
Number of patients 20 21 19 20 20 100
Gender
 Female (n) 11 10 11 9 15 56
 Male (n) 9 11 8 11 5 44
Age (years)
 Mean 59.1 59.6 65.7 60.0 61.6 61.1
 (min–max) (43–77) (41–86) (49–82) (41–86) (49–73) (41–86)
BMI (kg/cm2): Mean (SD) 27.4 (4.3) 28.1 (3.7) 30.1 (5.8) 26.9 (4.2) 31.2 (6.8) 28.7 (5.2)
Kellgren–Lawrence grade
 II (n) 11 14 9 14 11 59
 III (n) 9 7 10 6 9 41
Baseline knee pain (VAS): Mean (SD) 63.7 (8.3) 64.5 (8.8) 63.2 (9.5) 62.6 (8.6) 67.8 (8.3) 64.4 (8.7)